Clinical Research Directory
Browse clinical research sites, groups, and studies.
10 clinical studies listed.
Filters:
Tundra lists 10 NSTEMI clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT06528821
AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS
AI ECG TIMI is an investigator-initiated, international, and multicenter registry of acute coronary syndrome patients aimed to identify electrocardiographic findings detected by an AI model predicting coronary blood flow alteration. The aim of the study is to identify electrocardiographic findings detected by an automated artificial intelligence (AI) model that can predict coronary blood flow alteration as assessed by the TIMI grade flow at the very moment of the invasive coronary angiography in patients with acute coronary syndromes.
Gender: All
Ages: 18 Years - 85 Years
Updated: 2026-11-18
NCT07938060
Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE)
Coronary heart disease causes narrowing of the heart (coronary) arteries (arteries are blood vessels, which supply oxygen-rich blood to the heart muscle). Your heart specialist will have explained to you that they suspect that you have a narrowing in one or more of your heart arteries. This narrowing may be causing you to have chest pains or evidence of reduced blood supply to your heart muscle. One commonly used treatment for this problem is to stretch the narrowing with a balloon and then insert a small mesh-like device called a stent, which will hold the artery open, improving the blood flow to your heart, and thereby help with your symptoms. An alternative treatment is to open the narrowing with a balloon that is coated with an anti-inflammatory drug (so called drug-coated balloon) as treatment instead of a stent. Drug-coated balloons are used to reduce the risk of re-narrowing of your coronary arteries without leaving an implant (like a stent) behind. A stent (which is a foreign object that does not belong in the body) can cause vessel inflammation and it bears the risk of blockage within the stent (in-stent restenosis or ISR). Drug-coated balloons leave no implant behind but target the narrowing in your vessel wall with the delivery of an anti-inflammatory agent to the vessel wall, allowing the blood vessel to heal. Biosensors has developed a balloon coated with a drug called Biolimus A9™ which suppresses inflammation in the artery where the narrowing has occurred. We refer to this balloon coated with Biolimus A9™ as BA9-DCB (Biolimus A9™ drug-coated balloon) also known as BioRISE. This device is not commercially available and will be tested in this study for the first time in humans. However, several coronary stents made by Biosensors are already on the market that contain the Biolimus A9™ drug. It has been proven to be safe and effective in preventing re-narrowing of the artery where the stent is placed. In this study, two types of drug-coated balloons (DCBs) will be used; the BioRISE (test group; group 1) and SELUTION SLR, a balloon that is coated with sirolimus (control group; group 2). The SELUTION SLR balloon is commercially available in Europe. The study has the following design: • Patients will be treated according to standard hospital procedures using the study device. The study has the following design: * Patients will be treated according to standard hospital procedures using the study device. * There will be two different types of patients included in this study. * 400 patients with a narrowing in a heart artery that has never been treated before (referred to as de novo disease), of whom 200 will be treated with the BioRISE balloon and 200 with the SELUTION SLR balloon. The allocation to the two possible treatments is random as it must be in a study like this. Of these 400 patients, 15 in each treatment arm, will have the inside of the artery imaged during the procedure using a well-established technique called Optical Coherence Tomography (OCT) and Quantitative Flow Ratio (QFR) * 43 patients with a narrowing inside a stent that was implanted in the past (referred to as in-stent restenosis). In these patients, only the BioRISE balloon will be used. * Your doctor will explain to which category applies to you. * There will be up to 25 hospitals taking part in the study in the UK, and in up to 5 European countries * Patients will be taking part in the study for up to 3 years, and during this time their health status will be assessed by telephone or hospital visit at 1month, 9 month, 12 months, 24 months and 36 months. * There will be a check up angiography to assess the primary end point at 9 months for all participants.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-16
NCT07939516
Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Rationale Patients diagnosed with acute coronary syndrome (ACS), a sudden medical emergency where blood flow to the heart is blocked, require dual antiplatelet therapy (DAPT) for 12 months to prevent dangerous blood clots to form. This typically includes the combination of aspirin and a form of P2Y12 inhibitor, a specific type of medicine that stops platelet cells to clot. Irrespective of the treatment strategy (i.e., invasive through angioplasty or conservative with medication only), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events. Although ischemic complications (problems that happen when the heart doesn't get enough blood and oxygen) usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. However, in 30% of the (white) European patients, there is a small change (mutation) in their genetic material. They are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate processing of clopidogrel in to its active form. Despite knowledge of these loss of function mutations, current treatment guidelines for ACS do not provide specific recommendations on individualized, genotype-based treatment (i.e. using the unique genetic code to choose the medicine that works best) with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as they were too small and cautious to give definite answers. Objective The goal of this clinical trial is to investigate whether individualized genotype-guided treatment with DAPT after ACS diagnosis is just as safe and effective as standard clinical practice. Participants will receive: 1. Standard treatment at the discretion of the cardiologist, or 2. Genotype-guided treatment (based on the presence of a LOF allele) Participants included in the genotype-guided group who do not carry a LOF allele will be classified as normal processors of clopidogrel, and will de-escalate after 30 days from standard therapy to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started. Participants will be followed for 18 months after ACS diagnosis to collect medical data and to complete questionnaires.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-16
1 state
NCT07684742
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular ultrasound (IVUS)-guided drug-eluting stent implantation in patients with acute coronary syndrome. A total of 2,200 patients who achieve complete revascularization after IVUS-guided percutaneous coronary intervention (PCI) and meet the predefined successful IVUS-guided PCI criteria will be randomized in a 1:1 ratio to either the early single antiplatelet therapy group (Early SAPT: ticagrelor or prasugrel monotherapy) or the standard dual antiplatelet therapy group (Standard DAPT: aspirin plus ticagrelor or prasugrel). Randomization will be performed within 96 hours after completion of PCI, and clinical follow-up will be conducted at 1 month, 3 months, 6 months, and 12 months after randomization. The primary endpoints are major adverse cardiovascular events, defined as a composite of all-cause death, myocardial infarction, ischemia-driven target vessel revascularization, and definite or probable stent thrombosis occurring up to 12 months after randomization, and clinically relevant bleeding, defined as Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding occurring up to 12 months after randomization. This study aims to determine whether early P2Y12 inhibitor monotherapy is non-inferior to standard dual antiplatelet therapy (DAPT) for ischemic events and is superior in reducing clinically relevant bleeding.
Gender: All
Ages: 19 Years - Any
Updated: 2026-11-05
1 state
NCT06166407
Breisgau PHENO-HEART MI
Coronary heart disease and its acute complication, myocardial infarction (MI), represent the leading causes of death in Europe and the United States. Although novel treatment strategies have helped to improve survival in patients with MI, a large proportion of patients develops heart failure and is at risk of life-threatening arrhythmias. Complications arising after MI constitute a severe burden not only for the patients themselves, but also for health care systems worldwide. The likelihood of these complications depends on the area of myocardial tissue lost and the process of myocardial repair and scar tissue formation after MI ('remodeling') which are modified by the local and systemic immune response after MI. The immune response is critical after myocardial infarction. In particular, sustained overactive and prolonged inflammatory reactions lead to accentuated myocardial damage and dysfunction. Important mediators of the inflammatory reaction after MI are monocytes, T-cells, B-cells and hematopoietic stem and progenitor cells. Following MI, myeloid cells derived from the hematopoietic system drive a sharp increase in systemic leukocyte levels that correlates closely with mortality. T- and B-cells in particular act in response to specific antigens. Most of the data regarding the inflammatory response after MI, however, are derived from animal models. The immunological phenotypes after MI and their association with clinical outcome in humans are insufficiently characterized. Aims: The aim of this project is to provide establish clinically and immunologically well-characterized cohort of patients after MI This will aid in identifying novel prognostic cellular and humoral biomarkers that may be used to identify patients at a high inflammatory and immune risk and to guide clinical management. Furthermore, these mediators, in the future, may be targeted by novel antigen-specific immunomodulatory approaches. Patients with myocardial infarction (STEMI and NSTEMI) will be recruited after PCI within 24h and receive a structured follow-up. Clinical read-outs include a detailed and standardized patient history, clinical examination, standard blood work, coronary angiography, ECG, echocardiography and for subgroups, MRI. Patients will present for study visits at 6 weeks, 3 months and 12 months after the initial event. Blood will be sampled at the inclusion and during follow-up visits. Peripheral blood mononuclear cells and plasma will be stored at the Cardiovascular BioBank (CVBB) and FREEZE, both institutions at the University Hospital in Freiburg. Major adverse cardiac events (myocardial infarction, stroke, hospitalization for heart failure, cardiovascular death) will be recorded using telephone interviews and standardized queries to the local authorities. Several laboratory read-outs are planned including flow cytometry, mass cytometry, single cell RNA sequencing, T cell and B cell receptor sequencing and bulk-RNA-sequencing. In an initial approach we aim to recruit 400 patients with MI, of which we expect ≈40 to develop ischemic cardiomyopathy. Differences in immunological profiles between patients that develop MI and a propensity-matched control group will then be analyzed and correlated with clinical outcome data.
Gender: All
Ages: 18 Years - 85 Years
Updated: 2026-10-27
NCT07866144
Prediction of Adverse Events From Non-PCI Coronary Plaques Using Machine Learning
The aim of our project is to predict, with the help of artificial intelligence (AI) and machine learning techniques, the natural history of non-flow-limiting coronary stenoses and to develop and validate a machine learning risk score able to estimate the risk of MACE during follow-up based on OCT findings observed on coronary plaques not subjected to percutaneous coronary intervention (PCI) and on the clinical characteristics of the patients. We will collect information on all non-PCI coronary lesions assessed by performing OCT in non-culprit vessels of patients presenting with ACS or Chronic Coronary Syndrome (CCS) at the index procedure. All OCT runs will be digitized and analyzed with the help of AI. The OCT appearance of coronary plaques will be analyzed with AI and correlated with the risk of MACE during follow-up (a composite of cardiac death, myocardial infarction, or target lesion revascularization). An AI predictive risk model based on coronary plaque OCT images and patient clinical characteristics will be developed to estimate the risk of MACE incidence at follow-up. Cutting-edge machine learning algorithms, including convolutional neural networks, random forests, and support vector machines, will be used.
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-08
1 state
NCT05800951
Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock
The CERAMICS study is designed to more clearly delineate the current care of acute myocardial infarction with cardiogenic shock (AMICS) patients who are treated with mechanical circulatory support (MCS) devices in the United States with significant experience in MCS, all of whom have the capability of MCS escalation on-site. Study enrollment is targeted at 120 patients at 20 hospital sites, evaluating clinical outcomes, and focusing on outcomes MCS escalation decision making and ICU level management.
Gender: All
Ages: 18 Years - Any
Updated: 2026-04-17
11 states
NCT07343076
Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE II)
This is a prospective, multi-center, randomized controlled, open-label, blinded endpoint assessment study. The objective is to compare the 1-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE) between two treatment strategies-immediate complete revascularization and staged complete revascularization-in NSTE-ACS patients with multivessel disease (MVD). NSTE-ACS patients who meet other the inclusion and exclusion criteria will be randomized into the following two groups after signing an informed consent form: Intervention group Immediate Complete Revascularization: Emergency PCI for the culprit vessel is performed successfully, and simultaneous PCI is conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing). Control group During emergency intervention, PCI is performed only on the culprit vessel. Elective PCI is then conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥ 2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing)-either during the current emergency hospitalization or within 6 weeks after the culprit vessel PCI.
Gender: All
Ages: 18 Years - Any
Updated: 2026-01-30
NCT05764057
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors. There are no existing randomized clinical trials evaluating the efficacy and safety of dapagliflozin (nor any other SGLT2-inhibitor) to limit cardiac remodeling in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction. Preventing cardiac remodeling, an established predictor of subsequent heart failure (HF) and cardiovascular death, is likely to translate into benefit in reducing clinical events in post-MI patients.
Gender: All
Ages: 18 Years - Any
Updated: 2025-12-19
NCT04988672
OPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction
The purpose of the OPTIMISER Registry is to prospectively and retrospectively collect baseline, clinical and procedural data in patients who present with AMI and are treated with PCI as well as prospectively collect the clinical outcome data. Outcomes will be compared in different clinical subgroups. The impact of PCI in AMI in general as well as cardiovascular outcomes after AMI will be assessed.
Gender: All
Ages: 18 Years - Any
Updated: 2023-10-06